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Abstract
Background
Ecstasy use has been associated with short-term and long-term memory deficits on a stan-
dard Word Learning Task (WLT). The clinical relevance of this has been debated and is cur-
rently unknown. The present study aimed at evaluating the clinical relevance of verbal
memory impairment in Ecstasy users. To that end, clinical memory impairment was defined
as decrement in memory performance that exceeded the cut-off value of 1.5 times the stan-
dard deviation of the average score in the healthy control sample. The primary question
was whether being an Ecstasy user (E-user) was predictive of having clinically deficient
memory performance compared to a healthy control group.
Methods
WLT data were pooled from four experimental MDMA studies that compared memory per-
formance during placebo and MDMA intoxication. Control data were taken from healthy vol-
unteers with no drug use history who completed the WLT as part of a placebo-controlled
clinical trial. This resulted in a sample size of 65 E-users and 65 age- and gender-matched
healthy drug-naïve controls. All participants were recruited by similar means and were
tested at the same testing facilities using identical standard operating procedures. Data
were analyzed using linear mixed-effects models, Bayes factor, and logistic regressions.
Results
Findings were that verbal memory performance of placebo-treated E-users did not differ
from that of controls, and there was substantial evidence in favor of the null hypothesis. His-
tory of use was not predictive of memory impairment. During MDMA intoxication of E-users,
verbal memory was impaired.
Conclusion
The combination of the acute and long-term findings demonstrates that, while clinically rele-
vant memory impairment is present during intoxication, it is absent during abstinence. This
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suggests that use of Ecstasy/MDMA does not lead to clinically deficient memory perfor-
mance in the long term. Additionally, it has to be investigated whether the current findings
apply to more complex cognitive measures in diverse ‘user categories’ using a combination
of genetics, imaging techniques and neuropsychological assessments.
Introduction
The party drug Ecstasy was highly popular in the 1980’s and 1990’s and its use peaked in mid-
2000, after which it declined. Research in the Netherlands has shown that the percentage of
ecstasy tablets containing an MDMA-like substance was relatively high and stable (80 to
>95%) between 1999–2008 whereas it declined rapidly from 2008 on, a phenomenon also seen
in other EU countries [1]. Recent data has shown that the scenery has changed again with a
higher availability of pills with a high dose of MDMA and MDMA in powder- or crystal form
[2]. The Drug Information and Monitoring System in the Netherlands showed that while
ecstasy tablets up to 2009 contained less than 100 mg MDMA per tablet, this increased over
the last years with more higher dosed tablets (100 to> 150 mg MDMA) [3, 4].
As of 2015, Ecstasy use stabilized but annually still accounts for 1–3% of the general popula-
tion reported use in Europe, the US, and Australia demonstrating that a substantial proportion
of the population comes in contact with this substance once in their lives [2, 5–7]. It is known
that the percentage of E-users is higher in particular social settings. It has been shown in a
study amongst regular night clubbers that 37% of them used Ecstasy in the past year [2]. Smir-
nov et al. showed that young people’s Ecstasy use in general is relatively transient, that is, a
majority of young adult E-users consume Ecstasy relatively infrequently and have declining
levels of use before reaching their mid-twenties [8].
Ever since Ecstasy became popular, researchers have tried to uncover potential long lasting
negative effects of the drug on mental health and cognition (e.g., [9]). Of particular concern
has been the memory impairment, observed in abstinent (heavy) Ecstasy or E-users (e.g., [10–
14]). In general, two sources of evidence show that there is a relation between Ecstasy/MDMA
use and memory impairment. Firstly, placebo-controlled studies have shown that a single dose
of MDMA (75 mg) reduces verbal memory performance 1.5 hours after administration, as
indicated by a lower recall performance on an immediate and delayed recall test [15–19]. Con-
trolled MDMA administration studies also demonstrated that acute memory impairment was
transient in nature, that is, verbal memory performance was equal to placebo performance,
25.5 hours after MDMA administration [18]. Together these results indicate that MDMA is
able to temporarily distort verbal memory in light E-users and that a single dose in those users
does not lead to irreversible verbal memory impairment.
Secondly, retrospective studies in Ecstasy users have shown that these acute effects might
become chronic after long term use. Accordingly, Ecstasy use would cause impairments in
memory performance and/or changes in brain activation and structures that are important for
memory encoding and retrieval compared to control subjects (e.g. Ecstasy-naïve polydrug
users, cannabis users, or drug-naïve participants) ([20–23]; c.f. [24–26]). A meta-analysis by
Nulsen et al. (2010) showed that E-users performed significantly worse on short-term verbal
memory tasks compared to drug-naïve and polydrug controls. Short-term memory perfor-
mance was not predicted by life-time Ecstasy consumption which was between 1 and 1000 tab-
lets in total [14].
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Generally, these retrospective study designs encounter a number of methodological issues
such as polydrug use, impurity of tablets and unknown dose, reliability of self-reported drug
history, and (premorbid) group differences that may impede comparisons between groups and
interpretations of results [26, 27]. A number of these issues can be circumvented by prospective
studies in which a group of drug-naïve persons is followed in time and tested several times
before and after onset of Ecstasy use. Thus, it could be determined whether differences in cog-
nitive performance between E-users and non-users emerged before or after the onset of
MDMA use. In the ‘NeXT’ (the Netherlands XTC Toxicity) study, persons with a high proba-
bility to start using Ecstasy, as indicated by the intention to probably or certainly use Ecstasy in
the near future, were included [28, 29]. Schilt and colleagues (2007) showed that difference
scores of verbal memory between baseline and follow-up measures (within three years) were
significantly lower in the novice E-users (average lifetime use: 3.2 tablets) compared to the per-
sistent Ecstasy-naïve persons [29]. However, Krebs rightly remarked that the findings of this
nonrandomized study were overstated as all test scores were within the normal range. More-
over, the E-users did not deteriorate over sessions but the control group improved. Attention
was also drawn to the fact that some of the ‘novice’ users had used ten times more than the
group average and it could, therefore, not be qualified as low/light use. Furthermore, there
were no available data on the dose itself, and high doses cannot be excluded [30]. In another
prospective study, no effects of Ecstasy use on verbal memory were shown. In this study, how-
ever, the inclusion criterion ‘a high probability of future ecstasy use’ was, in contrast to Schilt
et al., operationalized as having first-hand but very limited experience with MDMA. The group
was split in two, based on the continuation of Ecstasy/MDMA use in the year following the
baseline assessment [31].
Despite these methodological differences between different prospective studies, and between
prospective versus retrospective studies, the results seem to point in the same direction. A sys-
tematic review of observational evidence concluded that, while verbal memory performance of
E-users differs from that of control subjects, the scores tend to fall within normal ranges, that
is, there is no solid evidence of clinical significance, and deficits are likely to be small [24].
While a meta-analysis of this kind provides valuable evidence, it encounters some difficulties
like heterogeneity in study design and measures, and unequal distribution of potential con-
founders in the study arms (e.g., age) [24]. In order to overcome these issues, the present data
analysis used linear mixed-effects models (LMEM) to account for variability that might be
introduced by confounds, such as, age, sex, and study (including unknown variations in experi-
menters, recruitment style, and population from which the sample was recruited).
The strength of the present study is that, in contrast to a common meta-analysis, this study
pooled the individual data from studies that used identical standard operating procedures at
identical test locations, same study design (e.g., placebo-controlled), using the same assessment
of memory performance (i.e., the Word Learning Task)[15–17, 19, 32–35]. In addition, com-
bining these datasets allowed the assessment of both the acute and long-term effects of MDMA
use in a large sample of E-users.
The main aim was to investigate the ‘long-term’ or chronic effects of low Ecstasy use on
memory performance. The research question was whether light polydrug E-users demon-
strated a great frequency of clinically relevant memory impairment than a healthy control
group. To that end, a ‘verbal memory impairment’ criterion was calculated that was used to sig-
nal clinical significance of the scores. Based on the literature about ‘Mild Cognitive
Impairment’ (MCI), objective memory impairment is defined as performance below a cut off
of 1.5 standard deviations of the average score in a healthy control sample [36, 37]. Although
this criterion is frequently used in clinical neuropsychology to indicate clinical neuropsycho-
logical deficits, it doesn’t imply that this cutoff is determinative with respect to functional
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abilities in daily life. Interestingly, studies of healthy elderly samples have shown that perfor-
mance in immediate verbal memory was the best predictor for activities of daily living [38].
Furthermore, it was also demonstrated that patients with MCI, performing minimally 1.5 SD
below the norm, do have functional impairments compared to a healthy control group [39].
Based on previous studies on E-users, it is hypothesized that, compared to a healthy control
group, E-users show lower memory scores. However, it was expected that the clinical signifi-
cance of these findings (e.g. functional impairment in daily life) was low as also suggested by
another meta-analysis [24]. Additionally, it was investigated whether quantifiers of Ecstasy/
MDMA exposure (i.e., ‘times used’ and ‘number of years of use’) contribute significantly to
long-term effects on memory performance as defined by clinically relevant memory deficits.
‘Short-term’ or acute effects of MDMA administration on clinical relevance of memory
impairment were also studied. Furthermore, it was investigated whether MDMA disposition
(MDMA blood concentrations) predict clinically deficient memory performance.
Materials and Methods
Participants
Two groups were included in the present study: Polydrug E-users from four placebo-controlled
experimental MDMA studies [15–17, 19] conducted between 2008 and 2012, and drug-naïve
participants from six placebo-controlled experimental studies investigating the acute effects of
medicinal drugs on cognition [33–35]. These ten separate studies were all approved by the
Medical Ethics Committee of Maastricht University and the University Hospital.
The pooled sample size from the MDMA studies was 70; five participants, however, partici-
pated in multiple MDMA studies so for them, only the first participation was included in the
analysis. The remaining 65 participants were matched by age and gender. In case there were
more matching options, the match was chosen randomly. In case there was no matching
option, the participant with the nearest age was randomly chosen so that the average age of
both samples was equal. Demographic details of E-users and matched controls are given in
Table 1. Drug use history (Table 2) was checked with a medical questionnaire and through an
interview with a medical doctor. The control participants were drug naïve and did not exces-
sively use alcohol (less than 20 alcoholic consumptions per week) as per the inclusion criteria.
Inclusion and exclusion criteria of all studies were identical apart from the drug use whereby a
history of illicit drug use resulted in the exclusion of participants from the control group.
Table 1. Demographic details of Ecstasy users andmatched controls.
E-users Matched Controls
Age
Mean (SD) 21.68 (2.11) 21.71 (2.13)
Min 18 18
Max 28 28
Gender
M:F 40:25 40:25
Education level
Missing data (%) 27.7 9.2
% related to non-missing data
- University students 38.3 47.8
- Non-University students 61.7 52.2
doi:10.1371/journal.pone.0149438.t001
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Participant recruitment in all studies was conducted by means of advertisements in the
buildings of Maastricht University, in local newspapers, an internet site (digiprik), and by word
of mouth.
Procedure
After enrolment in the separate studies, participants did a training session during which they
were familiarized with tests and test procedures. On the day prior to each test day, the use of
alcohol was prohibited. E-users were also asked to refrain from any drug use at least one week
prior to the medical screening until the last test day. Participants were instructed to arrive well-
rested (following a normal night’s sleep) at the test facilities; this was assessed by means of a
self-rated sleep scale. Participants were screened for alcohol and drug use in breath and urine
respectively at the start of a test day. When tests were negative they were allowed to proceed
with the test day. After a light breakfast and a mood questionnaire, participants in all studies
were given their ‘treatments’ (either active substance or placebo). At peak drug concentrations
the cognitive tests started. In all studies, the first neuropsychological assessment was the Word
Learning Task Immediate Recall (WLT-IR) test followed by 30 minutes of tasks after which the
Word Learning Task Delayed Recall (WLT-DR) test was conducted. In all the included experi-
mental MDMA studies, blood was drawn 1.5 hours after MDMA (75 mg) and placebo
Table 2. Drug use history (number of times used in lifetime) E-users.
Substance Min Max Mean (SD) Used
(N)
Never used
(N)
Missing data
(N)
Ecstasy/MDMA (number of times in lifetime) 1 780 30.28 (99.83) 64 n.a. 1¶
Ecstasy/MDMA (duration of use in years) 1 12 3.69 (2.24) 62 n.a. 3
Alcohol 60 2600 590.74
(592.58)
63* - 2**
Amphetamine 1 49 10.71 (14.20) 15† 50 n.a.
Cannabis 1 3650 236.18
(675.68)
57° 8 n.a.
Cocaine 1 40 13.61 (11.81) 24§ 41 n.a.
LSD 1 2 1.33 (0.58) 3 62 n.a.
Mushrooms/ ‘Magic Trufﬂes’ (psychoactive substance: psilocybine,
psilocine)
1 50 4.15 (8.32) 36$ 29 n.a.
Other:
- 2CB 2 2 2.00 1 64 n.a
- GHB (1: 20 times, other: no info) - - - 2 63 n.a
- Ketamine 5 10 7.50 (3.53) 2 63 n.a
- Salvia 1 1 1.00 1 64 n.a
¶ One participant stated using Ecstasy/MDMA ‘sometimes’ without putting it in numbers;
*36 participants did not quantify their use in numbers but stated to use alcohol on a ‘weekly’ base (N = 7), claimed that they use it ‘often’ (N = 17), deﬁned
their use as ‘average’ (N = 3), or stated using alcohol without putting it in numbers or quantifying it in words (N = 9);
**data about alcohol use was missing for 2 participants;
† 1 participant stated using amphetamines without putting it in numbers or quantifying it in words;
° 13 participants did not quantify their use in numbers but stated to use cannabis ‘once in a while’ (N = 2), ‘often’ (N = 5), ‘rarely’ (N = 1), ‘+100 times’
(N = 1), or stated using it without putting it in numbers or quantifying it in words (N = 4);
§ One participant stated using cocaine without putting it in numbers or quantifying it in words;
$ Two participants stated using ‘Magic Trufﬂes’ without putting it in numbers or quantifying it in words
doi:10.1371/journal.pone.0149438.t002
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administration, that is, prior to the WLT. For a detailed description of the toxicological deter-
mination, see [15–17, 19].
Word Learning Task
All of the studies included in this analysis used the same adapted version and procedure of the
Word Learning Task (WLT) [40]. There were parallel versions for separate test days. The WLT
consisted of thirty Dutch mono-syllabic meaningful nouns and adjectives that were consecu-
tively presented on a computer screen [16, 40]. Participants were to verbally recall as many
words as possible (immediate recall). This procedure was repeated three times; immediate
scores were summed to comprise the Total Immediate Recall score. After a 30-minute delay
participants were asked to recall as many of the previously learnt words as possible (delayed
recall). The dependent variables used for these analyses were the Total Immediate Recall (IR)
Score and the Delayed Recall (DR) Score.
Verbal Memory Impairment Criterion
A ‘verbal memory impairment’ criterion was calculated from age- and gender-matched verbal
memory performance data of the control sample. This cut off of objective impairment, based
on the literature on ‘Mild Cognitive Impairment’ was less than 1.5 standard deviations of the
average score in a healthy control sample [36, 37]. Using this criterion based on the scores of
the control group, scores in both the control group and the E-users group were classified into
two categories: impaired or not.
Statistical analysis
A Linear Mixed-Effects Model (LMEM) was performed to examine differences in verbal mem-
ory ability (i.e., immediate and delayed recall scores) between MDMA users and controls. The
LMEM approach was used to account for variability that may have been introduced by age,
sex, and study. The LMEM was fit to the data with fixed factor group (two levels: MDMA user,
control) and random factors study (ten levels), sex (two levels), and age (continuous) where sex
and age were nested within study (i.e., using the maximal random effects structure justified by
the experimental design, following [41]). A second LMEM was used to compare E-users on the
within-subjects fixed factor MDMA Treatment (two levels: MDMA, Placebo) and the same
random effects. The model was fit using the lme function of the nlme library [42, 43] for the R
package of statistical computing [44]. A separate LMEM was used to analyze each of our
dependent variables (immediate recall and delayed recall). F-statistics, significance values, and
effect sizes (generalized eta2) were calculated using Satterthwaite approximation for degrees of
freedom.
As classical null-hypothesis testing statistics are not designed to find evidence for an absence
of difference between conditions, the JZS Bayes factor was calculated to test the hypothesis that
MDMA users and controls do not differ in their immediate or delayed recall ability. The JZS
Bayes factor quantifies the strength of evidence in favour of the null hypothesis (when BF01<
1) or in favor of the alternative hypothesis (when BF01> 1; [45]). The Bayes factor was com-
puted using the ttestBF function for paired-samples designs in the BayesFactor library [46].
LMEM and Bayes factor analyses were performed using R statistical software (version 3.2.2).
Regression analyses were performed to determine relationships between drug use and verbal
memory performance. Several binary logistic regressions were conducted in order to test the
contribution of several factors to the chance of having clinical memory deficits immediately
after MDMA use, or in the long-term. The dependent variable was ‘verbal memory
impairment’ (yes/no); single predictors in the 5 separate analyses were ‘Ecstasy user’ (yes/no),
Ecstasy Use and Memory Impairment: A Clinical Perspective
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times used Ecstasy (number), years used Ecstasy (number), MDMA intoxication (MDMA/pla-
cebo), MDMA blood concentration (μg/L). Odds ratio (OR) together with 95% Confidence
Intervals (CI) are reported. Regression analyses were conducted using the statistical software
package SPSS (version 21.0). The significance level (alpha) for all tests was set at 0.05.
Results
Missing data
With regard to the behavioural data we had 65 complete sets for the IR-Score, and only 48
complete sets for the DR-Score since these data were not collected in one of the MDMA studies
[19]. Furthermore, data about life time Ecstasy use (times used/years of use) were missing for
four participants (one for ‘times used’; three for ‘years of use’), and MDMA concentrations
were missing for six participants. In case of missing data, specific analyses were run only
including complete data sets. WLT data of the 10 separate studies are shown in Table 3.
Long-term or chronic effects of Ecstasy use
E-users versus healthy controls. The LMEM yielded no significant differences between E-
users and healthy controls on measures of immediate recall [F (1, 9.08) = 0.24, p = .64, η2G =
.01] and delayed recall [F (1, 7.65) = 0.02, p = .89, η2G = .0004] (Fig 1, placebo scores). To test
whether there was evidence in favor of the null hypothesis for differences between E-users and
controls, the Bayes factor was calculated. There was substantial evidence for the null hypothesis
(see Jeffreys, 1961) for the immediate recall (BF01 = 4.36 ± 0%) and delayed recall (BF01 =
4.55 ± 0%) tasks. These results indicate that long-term MDMA use does not impair verbal
memory ability.
Ecstasy use and memory performance. The logistic regression analyses showed that
Ecstasy use per se did not statistically contribute significantly to the odds for having clinically
deficient immediate recall (OR = 2.63, 95% CI [0.49, 14.05], p = .26) and delayed recall
(OR = 0.67, 95% CI [0.06, 7.61], p = .75). Being an E-user, therefore, did not significantly pre-
dict having clinically relevant memory impairment (Fig 2).
Ecstasy exposure and memory impairment. Logistic regression analyses with clinical
impairment as the dependent variable and times used as the regressor showed that ‘times used’
did not significantly contribute to the odds for having clinically deficient immediate recall
(OR = 1.01, 95% CI [0.99, 1.02], p = .17) and delayed recall (OR = 0.72, 95% CI [0.34, 1.54], p =
.40). The logistic regression analyses including ‘years of use’ showed that this predictor also did
Table 3. Mean and standard deviation of immediate recall (IR) and delayed recall (DR) in the word learning task for each study.
Study E-user Control N Immediate RecallMean (SD) Delayed RecallMean (SD) N with IR impairment N with DR impairment
1 E 17 38.88 (11.42) - 1 0
2 E 17 42.47 (10.67) 13.94 (5.54) 1 0
3 E 16 38.87 (8.80) 12.25 (5.67) 2 1
4 E 15 54.07 (14.75) 20.07 (6.58) 1 0
5 C 6 37.00 (9.46) 10.00 (3.79) 0 0
6 C 7 40.14 (15.54) 13.86 (7.51) 0 0
7 C 8 54.00 (8.63) 21.12 (4.12) 0 0
8 C 13 41.69 (9.23) 13.85 (5.10) 0 0
9 C 14 52.93 (12.41) 18.79 (6.88) 2 1
10 C 17 44.82 (12.72) 15.82 (5.09) 0 1
doi:10.1371/journal.pone.0149438.t003
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not contribute to the chance of having clinically significant IR (OR = 1.02, 95% CI [0.69, 1.50],
p = .94) and DR memory impairment (OR = .66, 95% CI [0.15, 2.80], p = .57).
Short-term or acute effects of MDMA
MDMA intoxication and memory. LMEM analyses revealed significant main effects of
Treatment on IR Score [F (1, 65.5) = 18.90, p< .001, η2G = .06]) and DR Score [F (1, 48.7) =
21.55, p< .001, η2G = .07]. Participants recalled on average 6.90 fewer words during the imme-
diate recall, and 3.87 fewer words during the delayed recall, in the MDMA condition, compared
to the placebo condition (Fig 1). Logistic regression with clinical impairment as the dependent
variable and treatment (MDMA, placebo) as the regressor revealed that the impairment was
also of clinical relevance; MDMA intoxication contributed to the chance of having clinically
deficient memory performance during immediate recall (OR = 0.20, 95% CI [0.07, 0.58], p =
.003) and delayed recall (OR = 0.06, 95% CI [0.01, 0.51], p = .01) (Fig 2).
MDMA disposition and memory. LMEM analyses with MDMA blood concentration as
the dependent variable and clinical impairment (based on IR scores) as a fixed effect showed
no significant effect of clinical impairment [F (1, 64.81) = 1.17, p = .28, η2G = .04]. Bayes factor
t-tests revealed only anecdotal evidence for the null hypothesis for differences in MDMA blood
concentration between clinical relevance groups (BF01 = 2.03 ± 0.02%). Therefore, there is
weak evidence that clinically relevant memory impairments for immediate recall while under
the influence are not associated with a greater blood concentration of MDMA. These analyses
could not be performed for DR memory impairments because MDMA concentrations for
those with clinically relevant DR memory impairment were missing.
Discussion
The central question of the present study was whether being a light E-user increases the chance
of having clinically relevant verbal memory impairment. Results showed that memory perfor-
mance of E-users did not differ from that of matched controls and that it was well within the
normal range. Quantifiers of lifetime Ecstasy use (e.g., times used, years of use) did also not
increase the chance of having clinically deficient memory performance.
The absence of a persistent long-term effect of Ecstasy on memory performance might be
attributed to a difference in characteristics of the groups included in the present study and
those of previous studies. Rogers (2009) interestingly pointed at the fact that in previous retro-
spective studies, samples were not drawn from comparable populations and that Ecstasy–using
groups were on average less intelligent than their controls and tended to perform worse on
neurocognitive tasks [24]. In the present pooled data-analysis, samples were drawn from com-
parable groups. Participants in the studies were recruited using the same strategies and in the
same places (e.g., adverts at university and on a website digiprik.nl). All of the participants with
known ‘current occupation’ details were students. Second, E-users in the present study had a
low lifetime use history. Conceivably, the present sample was less exposed to potentially toxic
substances, as being light E-users, and accordingly light polydrug users. The interaction effects
of Ecstasy/MDMA with other co-consumed substances (e.g., alcohol, nicotine, cannabis) has
been understudied, though it has been hypothesized that it could lead to increased toxicity
and/or higher chance at compulsive use [47]. If this is indeed the case, more cognitive and
behavioral problems would be expected in a group with heavy use and co-use of substances. In
addition, light E-users probably haven’t been subjected to ‘aggregation toxicity’ to such an
extent as heavy users have. This term ‘aggregation toxicity’ was coined by amphetamine
researchers, almost 70 years ago, and refers to the fact that environmental factors linked to
party-settings like high ambient temperature, crowding, extensive dancing and little fluid
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intake, play a large role in the severity of neurotoxicity. This was at least shown in animal mod-
els, that is, preventing acute hyperthermia attenuated the long-termMDMA toxicity [48].
An alternative explanation may relate to task complexity. Previously, Brown and colleagues
have shown that memory tasks of higher complexity [49] showed reliable memory deficits in
‘moderate’ E-users. According to the criteria of the authors, our task would be classified as a
‘simple explicit memory’ task and therefore no differences between groups would be expected.
Fig 1. Themedian (red line), 25th and 75th percentiles (box edges), range excluding outliers (whiskers), and outliers (red +) of the Total Immediate
Recall (IR) Score (upper graph) and Delayed Recall (DR) Score (lower graph) of Controls, and Ecstasy users (E-Users) in the placebo condition
and MDMA condition.
doi:10.1371/journal.pone.0149438.g001
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However, Brown et al. (2010) did not test this assumption nor did they establish whether low-
use E-users were impaired in tasks of higher complexity. Furthermore, they only reported sta-
tistical significance levels and did not address clinical significance. In contrast, Bedi and col-
leagues (2008) showed that evidence for impairing effects of Ecstasy on higher-level cognitive
Fig 2. Frequency distribution of the raw IR (left panel) and DR (right panel) scores in the Ecstasy users during MDMA intoxication and placebo,
and healthy controls. The straight line represents the mean IR (left) or DR (right) score in the healthy control group, the dotted lines represent the memory
criterion, that is, 1.5 SDs of the healthy control group. Participants that fall on the left side of the left dotted line have impaired memory relative to the criterion;
participants that fall on the right side of the right dotted line have superior memory performance relative to the criterion.
doi:10.1371/journal.pone.0149438.g002
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functions in their study was weak after controlling for potential confounds, and moreover not
deemed to be of clinical significance [50].
A secondary question addressed in this study was whether MDMA intoxication leads to sta-
tistically and clinically significant memory impairment. Findings showed that it did. Where the
statistical significance was a confirmation of the findings from the pooled studies [15–17, 19],
the proof of clinical relevance was new. In addition, it was shown that MDMA blood concen-
trations during intoxication did not contribute to the chance of having clinically deficient
memory performance. More specifically, the level of exposure to this ‘toxic’ substance is not a
determinant of the chance of having clinically significant memory impairment; it is just the
exposure per se. It should be noted however that the range of MDMA blood-concentrations
was very small because all studies employed a single and identical dose, namely 75 mg. Our
findings, therefore, do not exclude the possibility that memory impairment will increase with
higher MDMA doses and/or blood-concentrations. Interestingly, the combination of the short-
term and long-term findings in the present study demonstrates that while clinically deficient
memory performance is present during intoxication, it is absent during abstinence. Together,
this could indicate that light Ecstasy use does not lead to clinically deficient memory perfor-
mance in simple explicit memory tasks in the long run. Preclinical research has also shown
that the acute MDMA effects on memory and learning are more extensive than the chronic
effects [51], although these studies have generally focused on the neurotoxic potential of
MDMA after high, non-human equivalent doses.
A potential limitation of the present study relates to the type of included user, that is, no
heavy users but only light (polydrug) E-users participated. Therefore results only pertain to
this particular group. On the other hand, not all E-users are heavy users and consequently the
general message about long-term effects must be nuanced and might not apply to light users.
Another limitation is that information on premorbid intelligence levels was not systematically
gathered in the pooled studies. Such information on baseline intelligence could provide addi-
tional evidence for howMDMAmay affect memory. However, statistical tests did show that
memory performance was similarly distributed for E-users when abstinent and the controls.
Participants in the pooled studies could therefore be regarded as similar in terms of cognitive
abilities. A third potential limitation is that we only collected data on the lifetime use and not
on the amount (number of tablets) of ecstasy/MDMA used. Gallagher and colleagues argued
that the number of tablets used is a better predictor than the estimated total lifetime use. They
showed that the typical ecstasy dose consumed in a single session is an important predictor of
prospective memory impairments with higher doses giving rise to greater impairment [52].
However, when knowing the amount of tablets taken, the exact dose of MDMA is still
unknown. A fourth potential limitation refers to the fact that only the Word Learning Test was
used. As mentioned above, it has been shown previously by Brown and colleagues that more
complex measures show impairment in E-users compared to drug naïve controls [49]. How-
ever, in that case, the clinical significance of effects also should be taken into account. A fifth
potential limitation is linked with the approach used by the present study, i.e. we do not con-
sider baseline levels of performance and it cannot be excluded that subtler deficits have an
impact on daily life activities in case this activities tap onto the assessed skill.
Future studies looking into long-term effects of Ecstasy use should gather additional genetic
information as it has been shown that specific genes in combination with life-time use charac-
teristics differentially influence memory performance in E-users [53]. Another related example
is genes determining metabolism rate and, consequently, neurotoxicological potential of
MDMA. Even though it was shown previously that one gene (CYP2D6) that is highly involved
in metabolic clearance of MDMA was of lower clinical relevance than previously predicted
[54], more research into similar genes could provide additional information on the relation
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between these and clinically relevant behavioral outcomes. Furthermore, preclinical studies
have shown that MDMA is able to influence the expression of serotonin-related genes [55, 56]
which might manifest as cognitive problems. So, next to genes, epigenetics will provide a more
detailed view on the mechanisms underlying potential impairment observed in E-users. Besides
genetics, it would be informative to include data on environmental circumstances linked to
drug use history (e.g., ‘aggregation toxicity’ [48], or taking ‘protective’ substances before/after
use [57]) to investigate the contribution of these factors to cognitive performance. However,
like drug history information, this information would be retrospective and subject to recall-
bias; nevertheless, it could be used as a covariate in statistical analyses (e.g., LMEM) next to
other demographic variables. Furthermore, inclusion of tasks of different complexity and brain
imaging measures could provide a more detailed picture on the potential impairing effect of
chronic Ecstasy use. It has been shown that behavioral measures can be less sensitive than
imaging measures in that aberrant functional patterns are shown in the absence of behavioral
effects (e.g., [20, 21]). However, with regard to the behavioral measure (verbal memory) used
in the present study it is interesting to note that at least in healthy older adults, performance in
immediate verbal memory was the best predictor for activities of daily living [38]. This suggests
that the outcomes in the Word Learning Task could also be predictive of functional outcomes
in daily life in the present sample of drug users. In conclusion, while the question of clinical rel-
evance of impairment is rarely addressed in studies evaluating the long-term effects of drug
use. The present study did address clinical relevance and showed that light use of Ecstasy/
MDMA does not lead to clinically deficient memory performance on the long-term, that is,
after 1–12 years of use. Future studies should adopt the combined approach of determining
clinical relevance together with statistical significance. Additionally, it has to be investigated
whether the current findings apply to more complex cognitive measures in diverse ‘user catego-
ries’ using a combination of genetics, imaging techniques and neuropsychological assessments.
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